SHAREHOLDER ALERT: Weiss Law Investigates iRobot Corporation
SHAREHOLDER ALERT: Weiss Law Investigates iRobot Corporation |
| [05-August-2022] |
NEW YORK, Aug. 5, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of iRobot Corporation ("iRobot" or the "Company") (NASDAQ: IRBT) in connection with the proposed acquisition of the Company by Amazon.com, Inc. (NASDAQ: AMZN). Under the terms of the merger agreement, the Company's shareholders will receive $61.00 in cash for each share of iRobot common stock owned. The transaction is valued at approximately $1.7 billion.
If you own iRobot shares and wish to discuss this investigation or have any questions https://www.weisslaw.co/news-and-cases/irbt Weiss Law is investigating whether (i) iRobot's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $61.00 per-share merger consideration adequately compensates iRobot's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed. Notably, at least one analyst set a price target for the Company of $75 per share, $14.00 above the per-share merger consideration. Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com.
SOURCE Weiss Law | ||
Company Codes: NASDAQ-NMS:AMZN, NASDAQ-NMS:IRBT |
View original content to download multimedia:© 2022 PR Newswire. All Rights Reserved.
FDA Approves First Targeted Therapy For HER2-Low Breast Cancer
